VANCOUVER, British Columbia, Aug. 08, 2022 (GLOBE NEWSWIRE) — Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), a homegrown, Canadian company licensed by Health Canada to produce natural, scalable, and accessible psychedelic and functional mushrooms, as well as synthetic formulations for transformational human experiences, is pleased to announce that it has…


Previous articlePT345 – Steve Thayer, Ph.D. – Vital Psychedelic Conversations
Next articlePsyBio Therapeutics Announces Expansion of Patent Portfolio with Additional Global Patent Applications